Dr. Rachel Yehuda to Lead Discussions on Therapeutic Application of Psychedelics
Additional Featured Speakers Include Dr. Julie Holland, Dr. Carl Hart and many more
DENVER, May 12, 2023 (GLOBE NEWSWIRE) — Today, Psychedelic Science 2023, the breakthrough psychedelic conference hosted by Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by Momentum Events, announced its sessions and events covering the latest developments in therapy for psychedelic practitioners at this year’s conference taking place June 19-23, 2023 in Denver, Colorado.
The Psychedelic Science 2023 Conference will feature 22 sessions and events covering advances in the potential therapeutic applications of psychedelics. Conference attendees, including therapists, psychedelic practitioners, and other healthcare professionals, will have an opportunity to participate in a variety of sessions that address the potential application of psychedelic therapy, integration of post-psychedelic treatment experiences, and community-oriented and cultural competence in therapy practices.
More information about Psychedelic Science 2023 programming can be found here.
PS2023 Featured Therapy and Practitioner Speakers include:
PS2023 Featured Therapy and Practitioner Sessions Include:
About Momentum Events
Founded in 2012, Momentum Events proudly serves our clients and produces events that attract the best and brightest minds who come together to share their knowledge, connect with the individuals that matter most and enjoy valuable experiences online or in real life. Whether we’re developing cutting edge conferences for the markets we serve, or producing a partner’s next event, Momentum leverages our best in class technology platforms, an assortment of virtual and live event third-party provider relationships, and the meticulous nature of our event planning mindset to deliver true, sustainable value for all stakeholders. www.momentumevents.com
About MAPS
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Since its founding, MAPS has raised over $140 million for psychedelic and marijuana research and education and has earned both the Guidestar Platinum Seal of Transparency and a 4-Star Rating from Charity Navigator.
CONTACT
PS2023@kcsa.com
SINGAPORE, June 23, 2024 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare…
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had…
Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and…
TAIPEI, June 22, 2024 /PRNewswire/ -- The prestigious 2024 Tang Prize Laureates have been announced,…
Afrezza® Afrezza® (insulin human) Inhalation Powder. Study proves inhaled insulin is as effective as usual…
PURCHASE, NY, June 21, 2024 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader…